UA130221C2 - Інгібітори шляху jak1 для лікування захворювання шлунково-кишкового тракту - Google Patents
Інгібітори шляху jak1 для лікування захворювання шлунково-кишкового трактуInfo
- Publication number
- UA130221C2 UA130221C2 UAA202104150A UAA202104150A UA130221C2 UA 130221 C2 UA130221 C2 UA 130221C2 UA A202104150 A UAA202104150 A UA A202104150A UA A202104150 A UAA202104150 A UA A202104150A UA 130221 C2 UA130221 C2 UA 130221C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pyrrolo
- pyrazol
- compound
- trifluoromethyl
- piperidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781877P | 2018-12-19 | 2018-12-19 | |
| US201962854801P | 2019-05-30 | 2019-05-30 | |
| US201962901377P | 2019-09-17 | 2019-09-17 | |
| PCT/US2019/067418 WO2020132210A1 (en) | 2018-12-19 | 2019-12-19 | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130221C2 true UA130221C2 (uk) | 2025-12-24 |
Family
ID=69326646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202104150A UA130221C2 (uk) | 2018-12-19 | 2019-12-19 | Інгібітори шляху jak1 для лікування захворювання шлунково-кишкового тракту |
Country Status (15)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
| WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| JP7591500B2 (ja) | 2018-08-10 | 2024-11-28 | アクラリス セラピューティクス，インコーポレイテッド | ピロロピリミジンｉｔｋ阻害剤 |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| US11596632B2 (en) | 2018-12-19 | 2023-03-07 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of gastrointestinal disease |
| UA130579C2 (uk) | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| WO2021072116A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| EP4351584A4 (en) * | 2021-06-07 | 2025-04-23 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE |
| EP4615440A1 (en) * | 2022-11-08 | 2025-09-17 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine compositions for treatment of itk mediated conditions |
| AU2024415240A1 (en) * | 2023-12-28 | 2026-07-30 | Aclaris Therapeutics, Inc. | Crystalline polymorph of an itk inhibitor |
| CN120699157B (zh) * | 2025-07-16 | 2025-12-16 | 安康市中心医院 | 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| CR20190156A (es) | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| CA3003283A1 (en) * | 2015-11-24 | 2017-06-01 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
| CA3045666A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| WO2018111327A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of jak inhibitors at the site of gastrointestinal tract disease |
| US11596632B2 (en) | 2018-12-19 | 2023-03-07 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of gastrointestinal disease |
-
2019
- 2019-12-19 US US16/720,465 patent/US11596632B2/en active Active
- 2019-12-19 PH PH1/2021/551455A patent/PH12021551455A1/en unknown
- 2019-12-19 WO PCT/US2019/067418 patent/WO2020132210A1/en not_active Ceased
- 2019-12-19 TW TW108146771A patent/TWI884142B/zh active
- 2019-12-19 EP EP19842939.1A patent/EP3897627A1/en active Pending
- 2019-12-19 CA CA3123596A patent/CA3123596A1/en active Pending
- 2019-12-19 MX MX2021007260A patent/MX2021007260A/es unknown
- 2019-12-19 KR KR1020217022692A patent/KR20210116487A/ko active Pending
- 2019-12-19 AU AU2019403304A patent/AU2019403304B2/en active Active
- 2019-12-19 SG SG11202106470TA patent/SG11202106470TA/en unknown
- 2019-12-19 CN CN201980090047.2A patent/CN113692278A/zh active Pending
- 2019-12-19 UA UAA202104150A patent/UA130221C2/uk unknown
- 2019-12-19 MA MA054544A patent/MA54544A/fr unknown
- 2019-12-19 JP JP2021535585A patent/JP7624922B2/ja active Active
-
2021
- 2021-06-15 IL IL284034A patent/IL284034A/en unknown
-
2023
- 2023-01-31 US US18/103,662 patent/US12150943B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3897627A1 (en) | 2021-10-27 |
| KR20210116487A (ko) | 2021-09-27 |
| JP2022514089A (ja) | 2022-02-09 |
| WO2020132210A1 (en) | 2020-06-25 |
| AU2019403304A1 (en) | 2021-07-08 |
| CA3123596A1 (en) | 2020-06-25 |
| CN113692278A (zh) | 2021-11-23 |
| TWI884142B (zh) | 2025-05-21 |
| TW202038944A (zh) | 2020-11-01 |
| US20200197399A1 (en) | 2020-06-25 |
| JP7624922B2 (ja) | 2025-01-31 |
| PH12021551455A1 (en) | 2022-04-18 |
| US20230172939A1 (en) | 2023-06-08 |
| SG11202106470TA (en) | 2021-07-29 |
| MA54544A (fr) | 2021-10-27 |
| MX2021007260A (es) | 2021-09-08 |
| AU2019403304B2 (en) | 2025-09-04 |
| US12150943B2 (en) | 2024-11-26 |
| US11596632B2 (en) | 2023-03-07 |
| IL284034A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12150943B2 (en) | JAK1 pathway inhibitors for the treatment of gastrointestinal disease | |
| KR102830476B1 (ko) | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 | |
| BR112020019814A2 (pt) | Tratamento de hidradenite supurativa usando inibidores jak | |
| CN114007621A (zh) | 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂 | |
| EA024743B1 (ru) | Соединение, предназначенное для лечения дегенеративных и воспалительных состояний | |
| BRPI0409124B1 (pt) | miméticos de direção inversa, biblioteca, uso destes e método relacionado aos mesmos | |
| BRPI0509888B1 (pt) | Compostos miméticos de direção inversa, composição farmacêutica e usos terapêuticos dos mesmos | |
| US20240390378A1 (en) | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) | |
| JP2010522697A (ja) | キナーゼタンパク質結合阻害剤 | |
| WO2021076124A1 (en) | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) | |
| KR20240009964A (ko) | 결절성 양진 치료를 위한 jak1 경로 억제제 | |
| EA048119B1 (ru) | Ингибиторы пути jak1 для лечения заболевания желудочно-кишечного тракта | |
| US20240307353A1 (en) | Jak1 pathway inhibitors for the treatment of asthma | |
| TW202419088A (zh) | 使用ｊａｋ抑制劑之蕁麻疹治療 | |
| EA050837B1 (ru) | Ингибиторы пути jak1, предназначенные для лечения связанных с цитокинами нарушений | |
| BR122025023186A2 (pt) | Uso de inibidores jak no tratamento de hidradenite supurativa |